全文获取类型
收费全文 | 3531篇 |
免费 | 304篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 222篇 |
妇产科学 | 49篇 |
基础医学 | 525篇 |
口腔科学 | 77篇 |
临床医学 | 363篇 |
内科学 | 857篇 |
皮肤病学 | 67篇 |
神经病学 | 143篇 |
特种医学 | 526篇 |
外科学 | 307篇 |
综合类 | 64篇 |
一般理论 | 4篇 |
预防医学 | 220篇 |
眼科学 | 30篇 |
药学 | 217篇 |
中国医学 | 3篇 |
肿瘤学 | 165篇 |
出版年
2022年 | 13篇 |
2021年 | 36篇 |
2020年 | 34篇 |
2019年 | 36篇 |
2018年 | 47篇 |
2017年 | 43篇 |
2016年 | 65篇 |
2015年 | 67篇 |
2014年 | 75篇 |
2013年 | 130篇 |
2012年 | 143篇 |
2011年 | 111篇 |
2010年 | 125篇 |
2009年 | 101篇 |
2008年 | 114篇 |
2007年 | 113篇 |
2006年 | 106篇 |
2005年 | 122篇 |
2004年 | 107篇 |
2003年 | 113篇 |
2002年 | 100篇 |
2001年 | 71篇 |
2000年 | 86篇 |
1999年 | 82篇 |
1998年 | 160篇 |
1997年 | 138篇 |
1996年 | 145篇 |
1995年 | 108篇 |
1994年 | 96篇 |
1993年 | 106篇 |
1992年 | 76篇 |
1991年 | 64篇 |
1990年 | 58篇 |
1989年 | 96篇 |
1988年 | 82篇 |
1987年 | 89篇 |
1986年 | 76篇 |
1985年 | 81篇 |
1984年 | 46篇 |
1983年 | 44篇 |
1982年 | 42篇 |
1981年 | 23篇 |
1980年 | 46篇 |
1979年 | 26篇 |
1978年 | 27篇 |
1977年 | 27篇 |
1976年 | 32篇 |
1975年 | 30篇 |
1972年 | 11篇 |
1968年 | 9篇 |
排序方式: 共有3859条查询结果,搜索用时 31 毫秒
1.
2.
3.
Mhd Wasem Alsabbagh Dana Church Lisa Wenger John Papastergiou Lalitha Raman-Wilms Eric Schneider Nancy Waite 《Research in social & administrative pharmacy》2019,15(2):202-206
Background
One approach to boost influenza vaccination coverage has been to expand immunization authority. In 2012, the province of Ontario gave community pharmacists the authority to administer the influenza vaccine.Objective
This study investigates the perspectives of Ontario pharmacy patrons, who had not recently received this vaccine from a pharmacist, regarding this pharmacist service.Methods
A survey was administered in six Ontario community pharmacies to pharmacy patrons who had not received an influenza vaccination from a pharmacist during the previous year. The instrument included questions about influenza vaccination, and knowledge of and attitudes toward vaccines and pharmacist-administered immunization.Results
A total of 541 pharmacy patrons completed the survey (53.9% response rate). About one-third (30.5%) of respondents were not aware that pharmacists could give the influenza vaccine, with younger individuals being less likely to be aware (OR 0.48, 95% CI 0.29–0.77, p?<?0.05) and less likely to receive the vaccine annually (OR 0.28, 95% CI 0.19–0.42, p?<?0.05). Leading reasons respondents gave as to why they did not receive their influenza vaccine from a pharmacist included not wanting or feeling they needed to be immunized (41.6%) and being used to receiving the vaccine from a physician (16.5%). Concerns about the experience and training of pharmacists and lack of privacy in a community pharmacy were uncommon.Conclusion
Reduced awareness of the availability of pharmacist-provided influenza vaccine is still common. Pharmacists have a significant opportunity to address lack of awareness and vaccine hesitancy issues. They can promote this service to increase influenza vaccination rates among pharmacy patrons who do not utilize this professional service. 相似文献4.
5.
JA HYEON KU CHEOL KWAK SEUNG-JUNE OH EUNSIK LEE SANG EUN LEE JAE-SEUNG PAICK 《International journal of urology》2004,11(7):489-493
BACKGROUND: Our aims in the present study were to estimate the influences of pain and urinary symptoms on quality of life, and to determine which of these two variables has the most predictive power with respect to quality of life in young men with chronic prostatitis-like symptoms. METHODS: Chronic prostatitis-like symptoms were measured by the National Institutes of Health-Chronic Prostatitis Symptom Index. Of the 28,841 men aged 20 years who lived in the study community, 18,495 men (a response rate 64.1%) agreed to participate in the study. A total of 1057 men who complained of symptoms indicative of chronic prostatitis were included in the study. The influences of pain and urinary symptoms on quality of life were determined using logistic regression analysis. The receiver operating characteristic (ROC) curve was used to estimate the predictive ability of each of these variables with respect to quality of life. RESULTS: Results from multivariate analysis showed that both pain and urinary symptoms were associated with an increased likelihood of impaired quality of life, although pain contributed more to a reduced quality of life than urinary symptoms. Relative to men who experienced mild pain, men who experienced moderate pain had a 3.9-fold risk of poor quality of life (odds ratio [OR], 3.87; 95% confidence interval [CI], 2.86-5.23; P < 0.001) and those who experienced severe pain had a 15.7-fold risk of reduced quality of life (OR, 15.68; 95% CI, 6.59-37.35; P < 0.001). Moderate urinary symptoms were associated with a 1.4-fold risk of bother (OR, 1.41; 95% CI, 1.01-1.99; P < 0.001) and severe urinary symptoms were associated with 2.4-fold risk (OR, 2.39; 95% CI, 1.37-4.12; P < 0.001), relative to mild urinary symptoms. Comparison of the effects of pain and urinary symptoms showed that pain severity had the most predictive power for bother, quality of life, and quality-of-life impact. The areas under the ROC curves for bother, quality of life, and quality-of-life impact were 71.3%, 69.3% and 72.5%, respectively. CONCLUSION: Urinary symptoms and pain might be associated with an increased likelihood of impaired quality of life in young men with chronic prostatitis-like symptoms. In addition, our findings suggest that pain severity is the most influential variable for determining quality of life in this population. 相似文献
6.
Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children 总被引:3,自引:3,他引:0
下载免费PDF全文
![点击此处可从《Antimicrobial agents and chemotherapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Brigitta U. Mueller Linda L. Lewis Geoffrey J. Yuen Maureen Farley Amy Keller Joseph A. Church Jonathan C. Goldsmith David J. Venzon Marc Rubin Philip A. Pizzo Frank M. Balis 《Antimicrobial agents and chemotherapy》1998,42(12):3187-3192
We studied the pharmacokinetics of intravenously and orally administered lamivudine at six dose levels ranging from 0.5 to 10 mg/kg of body weight in 52 children with human immunodeficiency virus infection. A two-compartment model with first-order elimination from the central compartment was simultaneously fitted to the serum drug concentration-time data obtained after intravenous and oral administration. The maximal concentration at the end of the 1-h intravenous infusion and the area under the concentration-time curve after oral and intravenous administration increased proportionally with the dose. The mean clearance of lamivudine (± standard deviation) in the children was 0.53 ± 0.19 liter/kg/h (229 ± 77 ml/min/m2 of body surface area), and the mean half-lives at the distribution and elimination phases were 0.23 ± 0.18 and 2.2 ± 2.1 h, respectively. Clearance was age dependent when normalized to body weight but age independent when normalized to body surface area. Lamivudine was rapidly absorbed after oral administration, and 66% ± 25% of the oral dose was absorbed. Serum lamivudine concentrations were maintained above 1 μM for ≥8 h of 24 h on the twice daily oral dosing schedule with doses of ≥2 mg/kg. The cerebrospinal fluid drug concentration measured 2 to 4 h after the dose was 12% (range, 0 to 46%) of the simultaneously measured serum drug concentration. A limited-sampling strategy was developed to estimate the area under the concentration-time curve for concentrations in serum at 2 and 6 h. 相似文献
7.
8.
9.
10.